August 2026 biopharma layoffs affect just over 500 workers, a 90% drop from a year earlier

In August 2026, twelve biotech and pharmaceutical firms announced workforce reductions, impacting a total of about 526 employees. This represents a sharp 90% decline in the number of people affected compared with the same month a year earlier.

The steep year‑over‑year decrease is largely due to the previous August’s large‑scale cut at CSL, which trimmed roughly 15% of its staff, an estimated 4,350 jobs. Without that event, the August 2026 impact would still have been higher than the current figure.

The most sizable layoff this month occurred at Blueprint Medicines, a Sanofi subsidiary. The company disclosed a WARN notice indicating that 229 positions at its Cambridge, Massachusetts headquarters will be eliminated, roughly a year after Sanofi completed a $9.5 billion acquisition of Blueprint.

The report also notes that three companies plan cuts that would reduce their workforces by more than half, though details on those reductions were not provided.